Nova Eye Medical: Profitability Inflection in a Nascent Glaucoma Market

After four years of >25% growth, the company delivers its first positive EBITDA and offers a clear path to sustained profitability.

EYE.AX · Earnings Call · 2026-08-03

The Promise Kept

Nova Eye Medical (EYE.AX) enters fiscal 2027 as a different company. The June quarter delivered the long-awaited milestone: positive EBITDA, after four consecutive years of >25% revenue growth. In the earnings call, CEO Tom Spurling summarized it bluntly: "We hit some major milestones in this last half, and we are different. We are combining profitability with sales growth just as we promised." The Interventional glaucoma market remains nascent, but the company's execution is now undeniable. The full-year revenue of $23.7 million (up 26%) closed at the top of guidance, with the U.S. – 79% of revenue – growing 30%. The second half benefited from the launch of two proprietary technologies: the Shear Clear technology, a shear-thinning viscoelastic that improves canal penetration, and the Green Light iTrack Advance, a navigational beacon that surgeons prefer over the previous red light. These product enhancements, combined with a nearly fully ramped sales force, drove a 21% quarter-on-quarter acceleration in the U.S. in Q4. The company's confidence is visible in its FY27 guidance of $26–$31 million (excluding China), implying 15–37% growth, with EBITDA again positive. Management deliberately left the range wide – "the top is what we think we can achieve, the bottom is what we know we can achieve" – but also provided a key leading indicator: annualized revenue per rep.

Sales Force Efficiency: The Hidden Lever

The crux of the new model is a highly productive, controlled U.S. sales force. On the call, Spurling emphasized "industry-leading revenue per rep," approaching $1.9 million per year. That figure is a deliberate target: when new territories are opened, the metric dips, but the payback is rapid. "Sales rep expansion in the United States does ultimately improve revenue," he noted in the February call, adding that the company adds reps "at a rate to ensure that our revenue per rep does not dramatically fall." The discipline is paying off – operating expenses are now clearly growing slower than sales, with sales and marketing costs down from 76% of sales in H1 FY24 to 52% in the latest half.

We hit some major milestones in this last half, and we are different. We are combining profitability with sales growth just as we promised.
Thomas Spurling, CEO · 2026-08-03

The company's reinvestment is selective. While spending on the licensed 2RT device was wound down (a conscious trade-off for near-term EBITDA), investment in iTrack continues. Spurling was candid: "We are not funded to be able to do it [2RT] as we've said a number of times. But in terms of iTrack, we aren't. We have an approved product." This prioritization – with cash on hand enough for 18 quarters of funding – underpins the guidance.

China Excluded, U.S. Dominant

Investors have repeatedly asked about China. The company has quietly deferred expansion there, with sales down 18% on a tiny base. "Our investments will be conducted very slowly because we get fast return at the moment in America and in Europe," Spurling said. The strategic decision is consistent with the push for profitability – while the market opportunity is real, the company has chosen to "exclude China from our guidance" until the cost structure justifies it. The U.S. is and will remain the engine. With Medicare reimbursement for 2027 essentially unchanged at a professional fee of $542, the revenue visibility is strong. The company's market share is still tiny – about 4-5% of U.S. interventional glaucoma procedures – but every percentage point gained translates directly into revenue and, increasingly, profit. In the prior quarter, the company had already laid the groundwork. On the February call, Spurling said "Sales rep expansion in the United States does ultimately improve revenue. There's no doubt about it." And in May, he discussed the temporary dip in revenue per rep due to weather and new hires, asserting the long-term trajectory. "We try and split the territories, give the person a lot of leads," he explained, reinforcing the deliberate approach. Today's numbers validate that patience.

Why It Matters

Nova Eye is a micro-cap with a market capitalization of roughly $35 million, but it has reached the critical inflection where growth and profitability co-exist. The company is riding the broader move toward minimally invasive glaucoma surgery – a theme Glaukos, its much larger competitor, has validated with a "very rosy outlook for interventional glaucoma," as Spurling noted. Yet Nova Eye differentiates on a tissue-sparing, implant-free platform. The consistent 25%+ growth, now paired with EBITDA positivity, makes this a compelling story for small-cap healthcare investors. The key number to watch is the quarterly U.S. revenue – as management itself suggests. With a new product cycle, full sales force coverage, and an explicit target to "lift" the lower end of guidance, the company is positioning itself to surprise on the upside.